MAPT and Alzheimer disease: No significant difference in reactivity was observed between the plasma samples from AD patients and non-AD controls in this small convenience cohort (Fig 5B), which is in line with the previous finding that the presence of autoantibodies targeting MTBD-tau is unrelated to AD or other neurological disorders.